Loading
A phase 2 trial of BL-B01D1 in triple-negative breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer is a phase 2 interventional study registered as NCT06471205 by Sichuan Baili Pharmaceutical Co., Ltd., with 52 participants planned, started 2024-08-02 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1 and PD-1 Monoclonal Antibody.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.